In May, Insys founder John Kapoor and four former executives were convicted of a racketeering conspiracy that boosted sales of the company’s liquid fentanyl painkiller, called Subsys.
The government failed to prove the defendants intended to commit bribery and extortion, so convictions of honest services fraud and of violating the Controlled Substances Act will be overturned, U.S. District Judge Allison Burroughs ruled Nov. 26 in Boston.
The convictions against Mr. Kapoor and the executives — Michael Gurry, Richard Simon, Sunrise Lee and Joseph Rowan — for wire and mail fraud will stand, according to NPR.
The judge said the government could have “easily” proved bribery, but chose not to charge for bribery or kickbacks, according to NPR.
She noted in her ruling that the decision was not intended to “condone or minimize” what Mr. Kapoor or the executives did when marketing Subsys.
The defendants are scheduled to be sentenced the second week of January 2020, according to NPR.
Read the full article here.
More articles on pharmacy:
Novartis pays $9.7B to acquire Medicines Co.
Drug importation plan will be released ‘soon,’ Trump tweets
From data analytics to biosimilars — How 5 pharmacy leaders are tackling drug pricing
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.